Rendu Biotechnology

Shanghai Rendu Biotechnology Co., Ltd. (Company abbreviation: Rendu Biotechnology, Stock code: 688193). Rendu Biotechnology was founded in 2007 and is a high-tech enterprise in China that focuses on RNA molecular diagnostic technologies and products. It is committed to developing and promoting RNA molecular diagnostic products based on real-time fluorescent isothermal amplification detection technology (referred to as SAT technology). Rendu Biotechnology owns a complete set of core technologies with independent intellectual property rights, ranging from diagnostic reagents to fully automatic supporting instrument research, development, and production. Currently, the company has successfully established the SAT technology platform, with 46 related patents authorized, and 20 products have obtained NMPA registration certificates and are being marketed and sold. Compared with DNA molecular diagnostic technology (PCR), SAT technology features high sensitivity, strong specificity, low cross-contamination, and ease of achieving fully automated high-throughput detection. Molecular diagnostic products based on SAT technology can be widely applied in clinical testing, blood screening, food safety testing, emergency prevention and control of infectious diseases, and rapid response, among other fields.